West Introduces Daikyo PLASCAP® RUV Closures in New Nested Format at Pharmapack
West Pharmaceutical Services (NYSE: WST) has announced the launch of Daikyo PLASCAP® Ready-to-Use Validated (RUV) closures in a new nested format at Pharmapack in Paris. The product, featuring multiple configurations, supports advanced therapies, particularly in cell and gene therapy treatments.
The PLASCAP® closure is a metal-free polypropylene cap with an integrated stopper, designed as a one-step press-fit solution for vial closure. It comes in ready-to-use, validated formats compatible with 13mm and 20mm crown vials. The new 6x8 nested tub configuration supports West 10ml nested CZ vials and selected nested vials with a 20mm crown.
West Pharmaceutical Services (NYSE: WST) ha annunciato il lancio dei tappi validati Daikyo PLASCAP® Ready-to-Use (RUV) in un nuovo formato nidificato a Pharmapack a Parigi. Il prodotto, dotato di molteplici configurazioni, supporta terapie avanzate, in particolare nei trattamenti di terapia cellulare e genica.
Il tappo PLASCAP® è un coperchio in polipropilene privo di metallo con un tappo integrato, progettato come soluzione di chiusura per fiale in un'unica fase di press-fit. È disponibile in formati pronti all'uso e convalidati, compatibili con fiale a corona da 13 mm e 20 mm. La nuova configurazione a tubi nidificati 6x8 supporta fiale CZ nidificate da 10 ml di West e alcune fiale nidificate con corona da 20 mm.
West Pharmaceutical Services (NYSE: WST) ha anunciado el lanzamiento de los tapones validados Daikyo PLASCAP® Ready-to-Use (RUV) en un nuevo formato anidado en Pharmapack en París. El producto, que presenta múltiples configuraciones, apoya terapias avanzadas, especialmente en tratamientos de terapia celular y genética.
El tapón PLASCAP® es un tapa de polipropileno libre de metal con un tapón integrado, diseñado como una solución de ajuste a presión de un solo paso para el cierre de viales. Viene en formatos listos para usar y validados, compatibles con viales de corona de 13 mm y 20 mm. La nueva configuración de tubo anidado 6x8 soporta viales CZ anidados de 10 ml de West y viales anidados seleccionados con corona de 20 mm.
웨스트 제약 서비스 (NYSE: WST)는 파리에서 열리는 Pharmapack에서 신규 중첩 형식의 Daikyo PLASCAP® 준비 완료 검증 폐쇄물 출시를 발표했습니다. 이 제품은 다양한 구성으로 제공되며, 특히 세폰과 유전자 치료의 고급 치료를 지원합니다.
PLASCAP® 폐쇄물은 금속 없는 폴리프로필렌 캡에 통합된 스토퍼로 설계되었으며, 바이알 폐쇄를 위한 원스텝 프레스 핏 솔루션입니다. 13mm 및 20mm 크라운 바이알과 호환되는 준비 완료 검증된 형식으로 제공됩니다. 새로운 6x8 중nested 튜브 구성은 웨스트의 10ml 중nested CZ 바이알과 20mm 크라운이 있는 선택된 중nested 바이알을 지원합니다.
West Pharmaceutical Services (NYSE: WST) a annoncé le lancement des bouchons validés Daikyo PLASCAP® Ready-to-Use (RUV) dans un nouveau format imbriqué lors du Pharmapack à Paris. Le produit, qui propose plusieurs configurations, soutient des thérapies avancées, en particulier dans les traitements de thérapies cellulaires et géniques.
Le bouchon PLASCAP® est un bouchon en polypropylène sans métal avec un bouchon intégré, conçu comme une solution d'ajustement en une étape pour le fermeture des flacons. Il est disponible dans des formats prêts à l'emploi et validés, compatibles avec des flacons couronnés de 13 mm et 20 mm. La nouvelle configuration de tubes imbriqués 6x8 prend en charge les flacons CZ imbriqués de 10 ml de West et certains flacons imbriqués avec une couronne de 20 mm.
West Pharmaceutical Services (NYSE: WST) hat die Einführung der validierten Daikyo PLASCAP® Ready-to-Use (RUV) Verschlüsse in einem neuen genesteten Format auf der Pharmapack in Paris bekannt gegeben. Das Produkt, das mehrere Konfigurationen umfasst, unterstützt fortschrittliche Therapien, insbesondere in der Zell- und Gentherapie.
Der PLASCAP® Verschluss ist ein metallfreier Polypropylenverschluss mit integriertem Stopfen, der als eine Schritt-Press-Fit-Lösung für die Vial-Verschließung konzipiert wurde. Er ist in gebrauchsfertigen, validierten Formaten erhältlich, die mit 13 mm und 20 mm Kronenfläschchen kompatibel sind. Die neue 6x8 genestete Röhrchenkonfiguration unterstützt Wests 10 ml genestete CZ-Fläschchen und ausgewählte genestete Fläschchen mit einer 20 mm Krone.
- Introduction of new product line supporting fast-growing advanced therapies sector
- Product compatibility with multiple vial formats enhancing market versatility
- Ready-to-use validated format reducing preparation time and complexity
- None.
Insights
The PLASCAP® closure is a metal-free polypropylene cap with an integrated stopper. This one-step press-fit solution for vial closure is offered in ready-to-use, validated formats compatible with vials with 13mm and 20 mm crowns. The new 6x8 nested tub configuration supports the West 10ml nested CZ vials as well as selected nested vials with a 20mm crown.
"West has been a leader in pharmaceutical packaging for over 100 years, and our containment solutions are used for the majority of gene and viral therapies in the market," said Stacey Vaughan, Vice President of Strategic Portfolio Management. "The introduction of this new nested format for our PLASCAP closures addresses the complex challenges of containment for advanced therapy molecules while meeting increasing regulatory requirements of the market."
For more information about PLASCAP® click here.
To learn more about West, please visit our website: www.westpharma.com.
Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "supporting," "addresses," "meeting," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that West's introduction of the PLASCAP® RUV closures in a new nested format will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.
Headquartered in
Crystal Zenith and PLASCAP are registered trademarks of Daikyo Seiko, Ltd. and are used under license.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-introduces-daikyo-plascap-ruv-closures-in-new-nested-format-at-pharmapack-302356582.html
SOURCE West Pharmaceutical Services, Inc.
FAQ
What is the new product West Pharmaceutical Services (WST) announced at Pharmapack 2025?
What are the key features of WST's new PLASCAP® closure system?
Which market segment is WST targeting with the new PLASCAP® nested format?
What vial configurations are compatible with WST's new nested PLASCAP® closures?
